Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution

BACKGROUND: Rheumatoid arthritis (RA) is a heterogeneous disease, as evidenced by the differences in long-term outcomes. This applies especially to anti-citrullinated protein antibodies (ACPA)-negative RA, where a proportion achieves sustained DMARD-free remission (SDFR; sustained absence of synovit...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstappen, M., van Steenbergen, H. W., de Jong, P. H. P., van der Helm-van Mil, A. H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722281/
https://www.ncbi.nlm.nih.gov/pubmed/34980246
http://dx.doi.org/10.1186/s13075-021-02671-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722281/
https://www.ncbi.nlm.nih.gov/pubmed/34980246
http://dx.doi.org/10.1186/s13075-021-02671-z

Ejemplares similares